SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects

Journal of Sleep Research

Volumn 10, Issue 2, 2001, Pages 129-142

  Pace Schott, Edward F ^a,c   Gersh, Tamara ^a   Silvestri, Rosalia ^b   Stickgold, Robert ^a   Salzman, Carl ^a   Hobson, J Allan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

Author keywords

Dreaming; Fluvoxamine; Paroxetine; Serotonin reuptake inhibitors

Indexed keywords

FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AMBULATORY MONITORING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DREAM; DREAMING; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECALL; REM SLEEP; SELF REPORT; SEROTONIN RELEASE;

NON-PROGRAMMATIC;

ADULT; DREAMS; FEMALE; FLUVOXAMINE; HUMANS; MALE; MENTAL RECALL; PAROXETINE; PERIODICITY; QUESTIONNAIRES; RANDOM ALLOCATION; SEROTONIN UPTAKE INHIBITORS; SLEEP, REM;

EID: 0034995817     PISSN: 09621105     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2869.2001.00249.x     Document Type: Article

References (77)

1. Nightcap: Laboratory and home-based evaluation of a portable sleep monitor
2. REM and NREM sleep reports: Comparison of word frequencies by cognitive classes
3. Dream recall and major depression: A preliminary report
4. Fluoxetine and oculomotor activity during sleep in depressed patients
5. The effects of fluoxetine on period-analyzed sleep EEG in depression
6. The cholinergic REM-sleep-induction test with RS86: State or trait marker of depression?
7. REM sleep in depression - An overview
8. Regional cerebral blood flow throughout the sleep-wake cycle
9. Serotonin reuptake inhibitor withdrawal
10. Pharmacokinetics of the selective serotonin reuptake inhibitors
11. REM sleep suppression and paroxetine
12. Withdrawal phenomena associated with antidepressant and antipsychotic agents
13. Fluoxetine-induced sleep disturbance in depressed patients
14. Neurotransmitter systems
15. The cholinergic REM induction test with arecholine in depression
16. Dream recall: History and current status of the field
17. A new model of brain-mind state: Activation level, input source, and mode of processing (AIM)
18. Activation, input source, and modulation: A neurocognitive model of the state of the brain-mind
19. The brain as a dream state generator: An actuation. Synthesis hypothesis of the dream process
20. Dream bizarreness and the activation-synthesis hypothesis
21. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups
22. Response to commentaries by Solms, Braun and Reiser
23. Consciousness: Its vicissitudes in waking and sleep
24. Dreaming and the brain: Toward a cognitive neuroscience of conscious states
25. The neuropsychology of REM sleep dreaming
26. The conscious state paradigm: A neurocognitive approach to waking, sleeping and dreaming
27. Structure and function of the brain serotonin system
28. Consciousness in waking and dreaming: The roles of neuronal oscillation and neuromodulation in determining similarities and differences
29. Medication and dreams: Changes in dream content after drug treatment
30. Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study
31. Fluvoxamine versus desipramine: Comparative polysomnographic effects
32. Nightmares related to fluoxetine treatment
33. Clinical neuropharmacology of sleep disorders
34. Fluoxetine and dreaming
35. Neuronal excitability modulation over the sleep cycle: A structural and mathematical model
36. Emotion profiles in the dreams of men and women
37. Modulation of rapid eye movement sleep in humans by drugs that modify monoaminergic and purinergic transmission
38. Mentation during sleep: The NREM/REM distinction
39. Mentation in REM and NREM sleep: A review and possible reconciliation of two models
40. Forebrain activation in REM sleep: An FDG PET study
41. REM sleep enhancement by bupropion in depressed men
42. Effects of paroxetine on human sleep
43. Enhancement of subjective intensity of dream features in normal subjects by the SSRIs paroxetine and fluvoxamine
44. Effects of selective serotonin reuptake inhibitors (SSRI) on dreaming in normal subjects
45. The fluoxetine-mediated increase in NREM eye movements can be detected in the home setting using the Nightcap
46. The Nightcap can distinguish patients with severe sleep disordered breathing (sdb) from patients with less severe sdb and controls
47. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortryptyline
48. Morphological substrate for eyelid movements: Innervation and structure of primate levator palpebrae superioris and orbicularis oculi muscles
49. The pharmacology of antidepressants at the synapse: Focus on newer compounds
50. Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine
51. Aricept-induced nightmares in Alzheimer's disease: 2 Case reports
52. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities
53. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder
54. Effect of pharmacological treatments on the sleep of depressed patients
55. Changes in sleep and dreaming during SSRI treatment and withdrawal in a home setting
56. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: A home-based evaluation during treatment and withdrawal
57. Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist
58. The effect of physostigmine on normal human sleep and dreaming
59. REM sleep induction by physostigmine during sleep
60. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: A double-blind randomized trial in major depression
61. A new paradigm for dream research: Mentation reports following spontaneous arousal from REM and NREM sleep recorded in a home setting
62. Longitudinal collection of mentation reports over wake-sleep states
63. Quantification of rapid eye movements with the Nightcap
64. Dreams are not produced without REM sleep mechanisms
65. Depression, sleep and antidepressants
66. Drug-induced nightmares
67. The effects of fluoxetine on the polysomnogram in outpatients with major depression
68. Drug effects on REM sleep and on endogenous depression
69. Bizarreness in dreams and fantasies: Implications for the activation-synthesis hypothesis
70. The organization of serotonergic projections to cerebral cortex in primates: Regional distribution of axon terminals